Exploration of immunologic mechanisms in psoriasis are in early stages of study, but promise to yield important clues to its pathogenesis, and more importantly, to direct the continued search for effective targeted drug therapies.
Results showed that apremilast met the primary end point achieving a statistically significant improvement in sPGA response at week 16 compared with placebo.
Aims of the study included measuring the strength of association between tumor necrosis factor inhibitor exposure and incident psoriasis and identifying clinical risk factors for psoriasis development.
The double-blind, placebo and active-controlled POETYK PSO-2 trial included 1022 patients 18 years of age and older with moderate to severe plaque psoriasis.
The correlation between physician-evaluated PASI and BSA involvement and patient-evaluated DLQI and PDI was evaluated in measuring psoriasis disease severity.
For patients discharged after acute ischemic stroke (AIS), the risk for stroke-associated pneumonia is reduced for those with psoriasis or other chronic inflammatory diseases.
